Loading stock data…
VRDN
$13.42-0.06 (-0.45%)
Market ClosedLast close May 1
Viridian Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $13.42. The stock is currently near its 52-week low of $11.76, remaining 44.8% below its 200-day moving average. Technical signals show oversold RSI of 28 and bullish MACD crossover, explaining why VRDN maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.42
Potential Upside
5%
Whystock Fair Value$14.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$33.56+150.1%
Range$20.00 – $50.00
Fundamentals
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.44%
Volume
Today's trading volume
1.36M
Recent News
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now. On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the stock. Despite the downward revision in target price, the stock still offers an attractive upside […]
Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock posted a 12.72% increment from a year ago, and a 51.76% year-to-date decline. Based on consensus, Wall Street analysts have an average price target of $32.33 for Viridian Therapeutics. In March, Viridian Therapeutics announced positive topline […]
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20%
The latest analyst coverage could presage a bad day for Viridian Therapeutics, Inc. ( NASDAQ:VRDN ), with the analysts...
Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $36 from $40 on April 8 but maintained a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings […]